We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.
- Authors
Chen, Wei; Shan, Boer; Zhou, Shuling; Yang, Huijuan; Ye, Shuang
- Abstract
<bold>Background: </bold>This study aims to evaluate the role of the fibrinogen/albumin ratio (FAR) in predicting platinum resistance and survival outcomes of patients with ovarian clear cell carcinoma (OCCC).<bold>Methods: </bold>Coagulation function and D-dimer, serum albumin, CA125 and HE4 levels were measured before surgery in OCCC patients undergoing initial surgery in our institution. FAR was calculated as fibrinogen/albumin level. The correlation between these indicators and clinicopathological features, platinum response, and survival outcomes was further analyzed. The Kaplan-Meier method and multivariable Cox regression model were used to assess the effects of FAR on progression-free survival (PFS) and overall survival (OS).<bold>Results: </bold>Advanced stage patients accounted for 42.1% of the 114 participants. Optimal cytoreductive surgery was achieved in 105 patients, and the complete resection rate was 78.1%. FAR was associated with tumor stage, residual tumor and platinum response. A receiver operating characteristic curve for predicting platinum response showed that the optimal cutoff point of the FAR was 12%. The sensitivity was 73.3% and the specificity was 68.2%. In multivariate analysis, FAR ≥12% (HR = 4.963, P = 0.002) was an independent risk factor for platinum resistance. In addition, FAR and D-dimer proved to be independent negative factors for outcomes including both PFS and OS. The median follow-up time was 52 months. A high FAR (≥ 12%) showed a stronger correlation with poor OS and PFS in the subgroup analysis of advanced and completely resected patients.<bold>Conclusions: </bold>The FAR might be a potential preoperative biochemical marker for predicting treatment response and oncological outcomes in OCCC patients.
- Subjects
FIBRINOGEN; PLATINUM; RECEIVER operating characteristic curves; ALBUMINS; HYPERTHERMIC intraperitoneal chemotherapy; SERUM albumin; OVARIAN surgery; THERAPEUTIC use of antineoplastic agents; ADENOCARCINOMA; PLATINUM compounds; OVARIAN tumors; PREDICTIVE tests; PREOPERATIVE period; ARTHRITIS Impact Measurement Scales; RETROSPECTIVE studies; TREATMENT effectiveness; DRUG monitoring; MEMBRANE proteins; TUMOR antigens; CYTOREDUCTIVE surgery; PROPORTIONAL hazards models; FIBRIN fibrinogen degradation products
- Publication
BMC Cancer, 2022, Vol 22, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-022-09204-0